Table 1.
Characteristic | N =155 |
---|---|
Females, n (%) | 86 (55%) |
Median age at diagnosis of inflammatory bowel disease (IQR) | 25 (18–36) |
Median age at time of initial test, years (IQR) | 39 (26–50) |
Smoking status, n (%) | |
Current | 82 (21%) |
Former (> 1 month with no smoking) | 24 (15%) |
Crohn’s disease | 121 (78%) |
Ileal | 19 (16%) |
Colonic only | 35 (29%) |
Ileocolonic | 67 (55%) |
Perianal disease | 29 (24%) |
Surgical management before anti-TNF | 65 (54%) |
Ulcerative colitis | 31 (20%) |
Left-sided disease | 7 (23%) |
Pan-colonic disease | 24 (77%) |
Indeterminate colitis | 3 (2%) |
Concomitant medication (at the time of initial test) | |
Mesalamine | 11 (7%) |
Corticosteroids (> 20 mg/day) | 16 (10%) |
Azathioprine/6-merca ptopuri ne | 57 (37%) |
Methotrexate | 12 (10%) |
Induction dosing (0, 2, 6 weeks) | 127 (82%) |
History of steroid pretreatment | 16 (10%) |
Initial response to infliximab | |
Complete response | 100 (65%) |
Partial response | 45 (29%) |
No response | 10 (6%) |
Median time to initial testing after infliximab initiation, weeks (IQR) | 50 (22.7–120) |
Median number of infusions (per patient) before test (IQR) | 8 (4–15) |
IQR, interquartile range; TNF, tumor necrosis factor.